Rocmira Pérez-Nicado
Finlay Institute(CU)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Bacterial Infections and Vaccines, vaccines and immunoinformatics approaches, Immunotherapy and Immune Responses
Most-Cited Works
- → SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies(2021)88 cited
- → Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform(2013)72 cited
- → New Vaccines Require Potent Adjuvants like AFPL1 and AFCo1(2007)59 cited
- → Biocompatible single-chain polymer nanoparticles loaded with an antigen mimetic as potential anticancer vaccine(2018)57 cited
- → A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial(2021)40 cited
- → Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials(2022)38 cited
- → A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity(2022)31 cited
- → A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles(2021)29 cited
- → Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children(2022)21 cited
- → Expanding the Scope of Ugi Multicomponent Bioconjugation to Produce Pneumococcal Multivalent Glycoconjugates as Vaccine Candidates(2020)20 cited